Form 4: IDEXX Laboratories Executive Vice President George Fennell Reports Stock Transactions
SEC Form 4 Filing
Executive Vice President George Fennell of IDEXX Laboratories reported the exercise of stock options and subsequent sale of shares on February 7th and 10th, 2025.
Summary
- George Fennell, an Executive Vice President at IDEXX Laboratories, reported transactions involving the company's stock.
- On February 7, 2025, Fennell exercised an incentive stock option to acquire 1,256 shares at a price of $79.54.
- On February 10, 2025, Fennell exercised a non-qualified stock option to acquire 9,986 shares at a price of $79.54.
- Also on February 10, 2025, Fennell sold 9,986 shares of common stock at a weighted average price of $462.5337 per share.
- Following these transactions, Fennell directly owns 8,176 shares of IDEXX Laboratories common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive, and does not inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common for executives at publicly traded companies like IDEXX Laboratories. These filings are monitored by investors for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The reported transactions are typical for executives who receive stock options as part of their compensation packages.
- Similar filings can be observed for executives at comparable companies in the animal health and diagnostics industries, such as Zoetis and Heska.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The impact on employees, customers, suppliers, and creditors is likely negligible.
Key Dates
| Date | Description |
|---|---|
| 02/14/2020 | Date that 628 shares of Issuer common stock vested in one installment. |
| 06/15/2015 | Date of 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock. |
| 02/14/2016 | Date that 9,986 shares of Issuer common stock vested in five annual installments beginning on this date. |
| 02/07/2025 | Date of incentive stock option exercise for 1,256 shares. |
| 02/10/2025 | Date of non-qualified stock option exercise for 9,986 shares and sale of 9,986 shares. |
| 02/11/2025 | Date of signature on the Form 4 filing. |
| 02/13/2025 | Expiration date of incentive and non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.